

CONAZ CREAM
Ketoconazole Cream 2% w/w
Module: 1

1.3 Product Information

1.3.1 Summary of Product Characteristics (SmPC)

1. NAME OF THE MEDICINAL PRODUCT

CONAZ CREAM (Ketoconazole Cream 2% w/w)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each gm cream contains:

Ketoconazole USP...20 mg

3. PHARMACEUTICAL FORM

Cream

A white semi-solid cream with a smooth texture.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Conaz cream is an antifungal medicine for the treatment of all kind of fungal or yeast infections of the skin. Infections may appear on the:

Trunk, chest or back;

Hands or feet;

Scalp or face;

Groin or genital;

Conaz cream works by killing the fungus that causes the infection.

For topical application in the treatment of dermatophyte infections of the skin such as tinea corporis, tinea cruris, tinea manus and tinea pedis infections due to Trichophyton spp, Microsporon spp and Epidermophyton spp. Conaz cream is also indicated for the treatment of cutaneous candidosis (including vulvitis), tinea (pityriasis) versicolor and seborrhoeic dermatitis caused by Malassezia (previously called Pityrosporum) spp.

CONAZ CREAM
Ketoconazole Cream 2% w/w
Module: 1

4.2 Posology and method of administration

Ketoconazole cream is for use in adults.

Tinea pedis:

Conaz Cream should be applied to the affected areas twice daily. The usual duration of treatment for mild infections is 1 week. For more severe or extensive infections (eg involving the sole or sides of the feet) treatment should be continued until a few days after all signs and symptoms have disappeared in order to prevent relaps.

For other infections:

Conaz cream should be applied to the affected areas once or twice daily, depending on the severity of the infection.

The treatment should be continued until a few days after the disappearance of all signs and symptoms. The usual duration of treatment is: tinea versicolor 2–3 weeks, tinea corporis 3–4 weeks.

The diagnosis should be reconsidered if no clinical improvement is noted after 4 weeks. General measures in regard to hygiene should be observed to control sources of infection or reinfection.

Seborrhoeic dermatitis is a chronic condition and relapse is highly likely.

Method of administration: Cutaneous administration.

Paediatrics

There are limited data on the use of ketoconazole 2% cream in paediatric patients

4.3 Contraindications:

Conaz cream is contra-indicated in patients with a known hypersensitivity to any of the ingredients or to ketoconazole itself.

4.4 Special warnings and precautions for use:

Conaz cream is not for ophthalmic use.

If coadministered with a topical corticosteroid, to prevent a rebound effect after stopping a prolonged treatment with topical corticosteroids it is recommended to continue applying a mild topical corticosteroid in the morning and to apply Conaz cream in the evening, and to subsequently and gradually withdraw the topical corticosteroid therapy over a period of 2-3 weeks

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, Pregnancy and lactation

There are no adequate and well-controlled studies in pregnant or lactating women. Data on a limited number of exposed pregnancies indicate no adverse effects of topical ketoconazole on pregnancy or on the health of the foetus/newborn child. Animal studies have shown reproductive toxicity at doses that are not relevant to the topical administration of ketoconazole.

Plasma concentrations of ketoconazole are not detectable after topical application of Conaz Cream to the skin of non-pregnant humans. There are no known risks associated with the use of Conaz Cream in pregnancy or lactation.

4.7 Effects on ability to drive and use machines

Conaz cream has no influence on the ability to drive and use machines.

4.8 Undesirable effects

The safety of ketoconazole cream was evaluated in 1079 subjects who participated in 30 clinical trials. Ketoconazole cream was applied topically to the skin. Based on pooled safety data from these clinical trials, the most commonly reported ($\geq 1\%$ incidence) adverse reactions were (with % incidence): application site pruritus (2%), skin burning sensation (1.9%), and application site erythema (1%).

Including the above-mentioned adverse reactions, the following table displays adverse reactions that have been reported with the use of ketoconazole cream from either clinical trial or postmarketing experiences. The displayed frequency categories use the following convention:

Very common ($\geq 1/10$)

Common ($\geq 1/100$ to $< 1/10$)

Uncommon ($\geq 1/1,000$ to $< 1/100$)

Rare ($\geq 1/10,000$ to $< 1/1,000$)

CONAZ CREAM
Ketoconazole Cream 2% w/w
Module: 1

Very rare (<1/10,000)

Not Known (cannot be estimated from the available clinical trial data).

System Class	Organ	Adverse Reactions		
		Frequency Category		
		Common (≥1/100 to <1/10)	Uncommon (≥1/1,000 to <1/100)	Not Known
Immune Disorders	System		Hypersensitivity	
Skin and Subcutaneous Tissue Disorders		Skin burning sensation	Bullous eruption Dermatitis contact Rash Skin exfoliation Sticky skin	Urticaria
General Disorders and Administration Site Conditions		Application site erythema Application site pruritus	Application site bleeding Application site discomfort Application site dryness Application site inflammation Application site irritation Application site paresthesia Application site reaction	

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

CONAZ CREAM
Ketoconazole Cream 2% w/w
Module: 1

4.9 Overdose

Topical Application

Excessive topical application may lead to erythema, oedema and a burning sensation, which will disappear upon discontinuation of the treatment.

Ingestion

In the event of accidental ingestion, supportive and symptomatic measures should be carried out.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antifungals for Topical Use, Imidazole and triazole derivatives

ATC Code: D01AC08

Usually ketoconazole cream acts rapidly on pruritus, which is commonly seen in dermatophyte and yeast infections, as well as skin conditions associated with the presence of *Malassezia* spp. This symptomatic improvement is observed before the first signs of healing are observed.

Ketoconazole, a synthetic imidazole dioxolane derivative, has a potent antimycotic activity against dermatophytes such as *Trichophyton* spp., *Epidermophyton floccosum* and *Microsporum* spp. and against yeasts, including *Malassezia* spp. and *Candida* spp. The effect on *Malassezia* spp. is particularly pronounced.

A study in 250 patients has shown that application twice daily for 7 days of ketoconazole 2% cream vs clotrimazole 1% cream for 4 weeks on both feet demonstrated efficacy in patients with tinea pedis (athlete's foot) presenting lesions between the toes. The primary efficacy endpoint was negative microscopic KOH examination at 4 weeks. Ketoconazole 2% treatment showed equivalent efficacy to 4 weeks clotrimazole 1% treatment. There was no evidence of relapse following treatment with ketoconazole cream at 8 weeks.

CONAZ CREAM
Ketoconazole Cream 2% w/w
Module: 1

5.2 Pharmacokinetic properties

Plasma concentrations of ketoconazole were not detectable after topical administration of Conaz Cream in adults on the skin. In one study in infants with seborrhoeic dermatitis (n = 19), where approximately 40 g of Conaz cream was applied daily on 40% of the body surface area, plasma levels of ketoconazole were detected in 5 infants, ranging from 32 to 133 ng/mL.

5.3 Preclinical safety data

Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.

6. Pharmaceutical particulars

6.1 List of excipients

Propylene glycol
Cetostearyl alcohol
Glycerol monostearate
Tween 60
Isopropyl Myristate
Sodium Sulfite anhydrous
Tween 80

6.2 Incompatibilities

None

6.3 Shelf life

3 years

6.4 Special precautions for storage

Store below 30°C. Protect from light.

CONAZ CREAM
Ketoconazole Cream 2% w/w
Module: 1

6.5 Nature and contents of container

20 gm Lacquer Coated Aluminum Tube

7. MARKETING AUTHORISATION HOLDER

JAWA INTERNATIONAL LIMITED

MANUFACTURER

JAWA INTERNATIONAL LIMITED
JAWA HOUSE,
PLOT 6, ABIMBOLA WAY,
ISOLO-INDUSTRIAL AREA
ISOLO.

CONAZ CREAM
Ketoconazole Cream 2% w/w
Module: 1

1.3.2 Labelling (outer & inner labels)

Enclosed